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Lymphatic filariasis is a major tropical disease caused by the mosquito-borne nematodes Brugia and
Wuchereria. About 120 million people are infected and at risk of lymphatic pathology such as acute lymphangi-
tis and elephantiasis. Vaccines against filariasis must generate immunity to the infective mosquito-derived
third-stage larva (L3) without accentuating immunopathogenic responses to lymphatic-dwelling adult para-
sites. We have identified two highly expressed genes, designated abundant larval transcript-1 and -2 (alt-1 and
alt-2), from each of which mRNAs account for >1% of L3 cDNAs. ALT-1 and ALT-2 share 79% amino acid
identity across 125 residues, including a putative signal sequence and a prominent acidic tract. Expression of
alt-1 and alt-2 is initiated midway through development in the mosquito, peaking in the infective larva and
declining sharply following entry into the host. Humans exposed to Brugia malayi show a high frequency of
immunoglobulin G1 (IgG1) and IgG3 antibodies to ALT-1 and -2, distinguishing them from adult-stage
antigens, which are targeted by the IgG4 isotype. Immunization of susceptible rodents (jirds) with ALT-1
elicited a 76% reduction in parasite survival, the highest reported for a single antigen from any filarial parasite.
ALT-1 and the closely related ALT-2 are therefore strong candidates for a future vaccine against human
filariasis.
Filarial nematodes are helminth parasites which are respon-
sible for lymphatic filariasis, a tropical disease afflicting some
119 million people (26, 28, 34). The parasites have a complex
life cycle in which mosquito-borne infective third-stage larvae
(L3) invade the human body, mature to adult worms, and
produce large numbers of newborn larvae (microfilariae)
which must transit the mosquito vector in order to develop to
L3 (16). Overt disease has a major immunopathologic compo-
nent, and a prominent risk of vaccination with filarial antigens
is exacerbation of pathology (22, 27, 32). The target of immu-
nopathological reactions, however, is thought to be the long-
lived adult worm and not the infective larva (23, 29).
To date, strategies to identify vaccine antigens in filariasis
have relied on serum antibodies to define antigens, whether by
comparing apparently uninfected subjects with infected pa-
tients (11) or by using sera from animals vaccinated with radi-
ation-attenuated parasites (19, 20). Among the antigens so
discovered have been several with high levels of similarity to
host antigens (such as muscle proteins), raising an additional
specter of autoimmune induction by vaccination. No recombi-
nant filarial antigen yet tested induces significant degrees of
immunity to challenge infection (21, 30), indicating that an
alternative criterion needs to be adopted.
We describe here a molecular biological approach, the anal-
ysis of mRNAs which are highly and selectively expressed by
the mosquito-derived larva at the time that it is competent to
infect the mammalian host. We sought to identify new antigens
which are restricted to this stage and absent from the mature
forms thought to evoke immunopathology. We also wished to
discover parasite-specific genes which carry minimal risk of
cross-reaction with host constituents. By using a PCR approach
with the conserved nematode 59-spliced leader and oligo(dT)
(12), we have previously reported the full-length cDNA se-
quences of two highly expressed genes, designated abundant
larval transcript-1 and -2 (13). ALT-1 and ALT-2 represent
closely related proteins (79% identity) and are homologous to
an abundant immunogen from larvae of the dog heartworm
Dirofilaria immitis (Di-20/22L) (10) and to proteins from the
additional filarial parasites Onchocerca volvulus (Ov-ALT-1)
(15) and Acanthocheilonema viteae (31). Most recently, the
SLAP (secreted larval acidic protein) produced by O. volvulus
larvae (2, 3) has also been shown to be a member of the ALT
family (Y. Wu and A. E. Bianco, personal communication).
Products associated with parasite invasion, which are tightly
regulated and parasite specific, are likely to be essential to the
success of parasitism (2). We describe here two related genes,
expressed strongly at the larval stage, which are prime candi-
dates for a new vaccine against filarial infection. The alt genes
represent attractive vaccine antigens for three reasons: (i) they
are larva specific in immunological terms; (ii) they are highly
expressed, offering an abundant target; and (iii) they have no
known homolog in the mammalian host.
MATERIALS AND METHODS
Parasites and infections of mosquitoes and jirds. Brugia malayi parasites were
obtained from TRS Laboratories and maintained by feeding Aedes aegypti mos-
quitoes with microfilariae in blood. Mosquitoes were maintained for up to 12
days and crushed to recover infective larvae by baermannization (13). Jirds were
infected with 300 infective larvae intraperitoneally, and peritoneal adult worms
and microfilariae were recovered 3 or more months later (1).
Genomic cloning. B. malayi genomic DNA was prepared as described previ-
ously (24) and used as the template for PCR with alt-1- and alt-2-specific primers
as follows: alt-1 forward (nucleotides [nt] 101 to 127 of cDNA), GAT GAC GAA
TTC GAC GAC GAA TCC TCA; alt-1 reverse (nt 433 to 407 of cDNA), TTG
TTT TGC TTG CTT TGT AAG CAT TTA; alt-2 forward (nt 102 to 128 of
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cDNA), GAC GAA GAG TTC GAT GAC TCC GCA GCC; and alt-2 reverse
(nt 443 to 417 of cDNA), GTA GTA TCA AAG ACT GAT TCA TTC CTA.
RT-PCR. For reverse transcription (RT)-PCR, first-strand cDNA was pro-
duced from total RNA using GeneAmp RT-PCR kits (Applied Biosystems,
Cheshire, U.K.) as previously described (13). PCR used the alt-1- and alt-2-
specific primers on first-strand cDNA for 35 cycles of 1 min at 99°C, 1 min at
55°C, and 1.5 min at 72°C.
Expression, antibody production, and Western blotting. The predicted mature
ALT-1 protein was expressed in the pET29 T vector (Novagen) as a fusion
protein with histidine and 15-amino acid (15-aa) S tag peptides. The PCR-
amplified alt-1 insert was directly cloned into the T overhang of the plasmid.
Expression was induced with 1 mM IPTG (isopropyl-b-D-thiogalactopyranoside)
at 37°C for 3 h. Bacteria were pelleted and sonicated, and the supernatant was
taken for metal-chelating affinity chromatography on His-Bind resin (Novagen).
BALB/c and CBA/Ca mice were immunized with 20 mg of recombinant ALT-1
(rALT-1) in complete Freund’s adjuvant (CFA), boosted 1 month later, and bled
7 days subsequently. Western blotting was performed with 6 mg of phosphate-
buffered saline-soluble protein extract from L3, mixed-stage adults, and micro-
filariae.
ELISA. Forty human sera from Sulawesi, Indonesia, were selected for testing.
Recombinant Bm-ALT-1 was coated at 1 mg/ml, a concentration determined to
be optimal in a pilot experiment. Isotype-specific monoclonal antibodies were
used as described previously (18). Recombinant Bm-33, an aspartyl protease
inhibitor (7), was expressed as a fusion protein with maltose-binding protein
(MBP) in the pMAL expression vector. rBm-33 and bacterially expressed MBP
were each used to coat enzyme-linked immunosorbent assay (ELISA) plates at
1 mg/ml, and anti-MBP responses were subtracted from those measured for
Bm-33/MBP fusion proteins.
Immunization. Male jirds (Meriones unguiculatus) were immunized with 75 mg
of rALT-1 in CFA subcutaneously or with CFA alone (six jirds per group). At
weeks 32 and 33, boosts were given of 25 mg of rALT-1 in incomplete Freund’s
adjuvant (IFA) or IFA alone, and at week 45 a final boost of 7.5 mg in IFA was
given. Two weeks later, all jirds were challenged with 300 larvae of B. malayi
introduced intraperitoneally. After 4 weeks, jirds were euthanized, and parasites
were recovered from the peritoneal cavity and testes. Parasite recoveries and
counting were performed without knowledge of the experimental status of each
animal.
Nucleotide sequence accession numbers. The genomic nucleotide sequences
for alt-1, alt-2a (1,075-bp band), and alt-2b (1,212-bp band) have been deposited
in the GenBank database under accession numbers AF183572, AF183573, and
AF183574, respectively. The cDNA sequence for alt-2 has been deposited in the
GenBank database under accession number U84723.
RESULTS AND DISCUSSION
Abundance of alt mRNA. The alt-1 gene was originally iden-
tified as a prominent trans-spliced mRNA from L3 larvae of B.
malayi (13), and alt-2 was identified as a closely related ex-
pressed sequence tag (EST) from the same stage. Since then,
the Filarial Genome Project has deposited over 18,000 ESTs
from all stages of this parasite (33). Analysis of this database
reveals that alt-1 is represented by 33 of 2,378 ESTs (1.39%)
from the L3, and alt-2 is represented by 67 of 2,378 (2.82%).
The alt-2 and alt-1 transcripts are, respectively, first and third
in abundance among all L3-expressed cDNAs in the EST data-
set (J. E. Allen, J. Daub, D. Guilliano, A. McDonnell, M.
Lizotte-Waniewski, D. Taylor, and M. Blaxter, submitted for
publication). Remarkably, neither cDNA can be found among
the 14,000-plus sequences derived from other points in the life
cycle, implying that alt-1 and alt-2 are expressed at less than
0.01% of mRNAs in non-L3 stages.
alt-like gene in Caenorhabditis elegans. alt-1 and alt-2 cDNA
sequences encode novel proteins each with signal sequences
and N-terminal acidic tracts, which share 79% amino acid
identity (13), and similar proteins have been described in other
filarial species (10, 15, 31). Alignment of these shows that
among the filarial parasites the acidic tract is highly variable,
but the remainder of the protein is conserved (Fig. 1A).
Among the predicted protein sequences from C. elegans de-
posited in WormPEP, only distant similarities could be found
with low significance (P $ 0.18), including two genes desig-
nated as phospholipase A2. However, when the complete nu-
FIG. 1. (A) Sequences of B. malayi ALT-1 (U57547) and ALT-2 (U84723)
compared to W. bancrofti ALT-1 (AF084553; R. Sabarinathan and P. Kalikraj,
Anna University, Madras, India, unpublished) and C. elegans cosmid CO8A9.
Alignments with D. immitis and O. volvulus have been published previously (13,
15). Note that the intron position in W. bancrofti has not been determined. (B)
Evidence for expression of the C. elegans alt homologue, a 240-bp PCR product
representing cDNA from mixed-stage C. elegans. Note the 289-bp band repre-
senting genomic DNA.
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cleotide sequence of C. elegans was searched, a more signifi-
cant similarity (P , 1026) was found on cosmid C08A9. This
cosmid contains a short tract corresponding to the second and
third exons of Bm-alt-1/2 and encodes a predicted peptide
sequence with 32% amino acid identity with Bm-ALT-1 (Fig.
1A). Moreover, C08A9 shows exact alignment of all cysteine
residues with Bm-ALT-1/2 and includes introns in identical
positions to those determined for Bm-alt-1/2. Curiously, no
upstream reading frame encoding an acidic domain could be
identified in 3 kb 39 of the homologous sequence.
Although not previously recognized as an open reading
frame (and hence not included in WormPEP), we established
that the C. elegans gene designated Ce-alt-1 is expressed in the
free-living organism: amplification of mixed-stage cDNA with
Ce-alt-1-specific primers gave a band with a size fully consistent
with correct splicing, as well as a larger band corresponding to
the genomic copy (Fig. 1B). Sequencing of the cDNA band
confirmed the splicing of the predicted intron (intron 2). This
may provide a route for future work aimed at discerning the
biological function of the ALT proteins.
Variant intronic sequences for alt-1 and alt-2. We amplified
genomic PCR products for each gene to characterize gene
structure, compare intronic structure, and design suitable
primers for RT-PCR. Both genes contained two introns, which
show no similarity between the two genes, with intron-exon
boundaries conforming closely to the consensus described for
Brugia genes (36). However, two products were observed from
genomic PCR for alt-2 (Fig. 2A), and this was found to be due
to a dimorphism in the second intron of alt-2 (Fig. 2B). Both
alt-2 introns are unusual in consisting largely of 27- or 46-nt
repeat units (Fig. 2B). The dichotomy in alt-2 is due to the
presence of either six or nine copies of the 46-bp repeat (Fig.
2B), and individual parasites possess either or both isoforms,
indicative of a Mendelian polymorphism.
Stage-specific gene expression. Expression of alt-1 and alt-2
at different points of the filarial life cycle was assessed by
RT-PCR. Primers designed to span the introns defined above
were used with the stage-specific cDNA libraries prepared by
the Filarial Genome Project. From these, alt-1 expression was
shown to be strictly L3 specific, and alt-2 largely so, although
trace levels of amplification were evident in other stages (Fig.
3A). To provide greater detail, freshly prepared first-strand
cDNA was taken at daily intervals during development of par-
asites from the microfilarial stage to the infective larva in A.
aegypti vector mosquitoes (Fig. 3B). This showed that both
alt-1 and -2 are switched on between 5 and 6 days following
uptake into the mosquito vector and remain expressed for the
duration of tenure in the insect. Similarly, parasites were re-
covered following infection of the rodent host M. unguiculatus
(the jird or Mongolian gerbil). Here, alt-1 expression termi-
nated abruptly on transfer into the jird; although brief periods
of transcription were detected between days 4 and 8, no sub-
sequent expression could be detected (Fig. 3C). alt-2 transcrip-
tion was less rigorously controlled, with expression continuing
for 3 days postinfection and recurring at intervals over the
following 3 weeks.
Antibodies to recombinant ALT-1 protein reacted specifi-
cally with a doublet of 20 kDa in soluble extract of L3 on
Western blots (Fig. 3D), but no reactivity was detectable to-
wards extracts of microfilariae and adult stages. Thus, at the
protein level, ALT-1 and -2 are effectively L3 specific. This
concords with the larva-specific expression of the related Di20/
22L proteins in D. immitis (9, 10) and of the secreted larval
acidic protein of O. volvulus (3), both of which are released
from larvae once they are cultured under mammalian condi-
tions. Although ALT proteins have not been identified on the
surface of B. malayi larvae, immunoelectron microscopy has
revealed intense staining with anti-Bm-ALT-1 antibody in the
larval glandular esophagus, implying that this product may also
be stockpiled ready for release within the mammalian host
(A. E. Bianco, G. Egerton, W. F. Gregory, R. M. Maizels, and
Y. Wu, unpublished observations).
Human recognition. The prominence of the alt transcripts
suggests that exposed humans may be serologically reactive to
the ALT proteins. We tested sera from 40 patients resident in
a B. malayi-endemic area of Indonesia, drawn equally from the
two categories of amicrofilaremic and microfilaremic. The
former group will contain both parasite-free individuals and
subjects with subpatent infections; the latter group all have
detectable blood-borne microfilariae. In patients with filariasis,
FIG. 2. (A) PCR of B. malayi genomic DNA amplified with (track 1) alt-1-specific primers and (track 2) alt-2-specific primers. Sizes are shown in base pairs. (B)
Schematic of gene structure of alt-1 and two alt-2 variants, and the repeat motifs found in the alt-2 introns.
4176 GREGORY ET AL. INFECT. IMMUN.
it is well established that the overwhelming proportion of an-
tibodies to crude adult and microfilaria-stage antigens are of
the IgG4 isotype (14, 18, 25).
Antibodies to rALT-1 protein were found in members of
both groups (Fig. 4). Interestingly, the antibody isotypes are
predominantly IgG1 and IgG3, and no IgG4 is observed. Re-
combinant proteins associated with the adult stage of B. ma-
layi, such as Bm33 (7), are generally recognized by IgG4 iso-
type antibodies (Fig. 4). There is also a discordance with
observations on the O. volvulus protein Ov-ALT-2 (86% iden-
tical to but eight amino acids smaller than Ov-ALT-1). This is
constitutively expressed (15), and human onchocerciasis pa-
tients have high levels (95%) of seropositivity, including IgG4.
Thus, in O. volvulus, ALT may not represent a larva-specific
antigen.
Protective immunization. B. malayi infects only certain host
species, among them the jird, which has been used as a model
for human filariasis (1). We immunized jirds with four doses of
ALT-1 and challenged them with 300 live L3. Four weeks later,
76% fewer live parasites were recovered from the immunized
group versus the adjuvant-only controls (Fig. 5). This differ-
ence was significant (P , 0.05) by Whitney-Mann nonparamet-
ric statistics. The data reported here indicate greater than 70%
protection in jirds against a challenge infection; this is substan-
tially better than any previous filarial recombinant antigen
reported and is in the range achieved by vaccination with
radiation-attenuated larvae, 44 to 91% (35). Of the previously
tested antigens, paramyosin has yielded disappointing results
(20, 21), while heat shock protein 70, myosin, and a1-type IV
collagen have recently been shown not to stimulate protective
immunity (30). Thus, ALT-1 and ALT-2 offer the best vaccine
candidates yet found for filariasis.
Conclusion. Vaccination against helminth parasite organ-
isms has proved problematic, both in identifying likely vaccine
antigens from the wide repertoire of antigens expressed and
with respect to the immunopathological responses to many of
these antigens (22). We report here a new approach, selecting
highly expressed, stage-specific products such as the ALT pro-
teins, which we show are not present in the mature adult stage.
This, coupled with the fact that ALT proteins are parasite-
FIG. 3. Expression around the life cycle. (A) Library PCR using alt-1- and alt-2-specific primers on B. malayi cDNA libraries from microfilariae (MF), L2, L3, and
adult male and female parasites. (B) RT-PCR of first-strand cDNA prepared from B. malayi parasites recovered from mosquitoes on successive days following feeding
of microfilariae to A. aegypti. U, uninfected mosquitoes. (C) RT-PCR of first-strand cDNA prepared from B. malayi parasites recovered on successive days following
infection of jirds with L3. Day 0, mosquito-derived L3. (D) Western blot with anti-ALT-1 and protein extracts from B. malayi L3, adult worms, and microfilariae, No
reactivity was seen with normal mouse serum.
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specific products unrelated to any host constituent, renders less
likely any adverse consequences of immunization. There is
evidence from two other filarial species to associate ALT rec-
ognition with immunity (8–10, 15), but the data given here
provide the first demonstration of protective immunity in a
susceptible host. The high level of sequence similarity between
ALT sequences from B. malayi and W. bancrofti suggests that
there will be immunological cross-protection between these
two species, one of which (W. bancrofti) is responsible for
.90% of human infections but does not infect laboratory an-
imals.
The human antibody profile supports, in the context of nat-
ural exposure, the concept that ALT-1 is an L3-specific anti-
gen, as we have previously shown that responses to L3 overall
are less dominated by IgG4 (17). It is notable that both micro-
filaria-negative and -positive groups contain individuals sero-
positive for ALT-1 antibodies. This finding is in keeping with
the notion of age-acquired concomitant immunity, in which
exposed individuals gain protection against new infection while
being unable to eradicate the resident parasites (4–6). Thus,
both normal subjects from endemic areas and microfilaria car-
riers may express protective antibodies, effectively negating the
search for protective antigens by comparing antibodies from
FIG. 4. ELISA using 40 human B. malayi filariasis sera against ALT-1 and Bm-33 proteins. Upper panels show sera from amicrofilaremic normal subjects where
filariasis is endemic; lower panels show sera from patients with circulating microfilariae. Horizontal bars in ALT-1 panels represent the mean value 1 3 standard
deviations of nonendemic control human serum reactions. Values for Bm-33 represent the net optical density (OD) following subtraction of readings for each serum
against its fusion protein partner, MBP.
FIG. 5. Immunization of jirds (M. unguiculatus) with ALT-1. Groups of six
jirds were immunized with either ALT-1 in CFA or CFA alone, boosted with
ALT-1 in IFA or IFA alone, and challenged with 300 B. malayi L3. After 28 days,
the number of parasites recovered were counted. Data from individual animals
are plotted, with geometric means shown as bars. The two groups are signifi-
cantly different by the Mann-Whitney nonparametric test (P , 0.05).
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“immune” and “susceptible” individuals; such a comparison
would have excluded ALT-1 from consideration.
The conservation of alt genes in all the filarial nematodes so
far studied and the very weak similarity to a single C. elegans
locus imply that ALT products are critical in a filaria-specific
role. Moreover, this role evidently requires a remarkably high
degree of expression at the point of initial entry by parasites
into the mammalian host. If this role is essential to parasite
survival, neutralization by the immune response may be suffi-
cient to ensure protection. Elucidation of the function of the
ALT proteins and the nature of the response induced by vac-
cination with these antigens should greatly enhance our under-
standing of the immunology of filarial infection and may lead
to successful strategies for the control of filarial disease.
ACKNOWLEDGMENTS
We thank the Wellcome Trust, the Medical Research Council, and
the European Commission for support under the INCO-DC pro-
gramme.
We also thank Mark Blaxter, David Guiliano, Xing-xing Zang, and
Maria Yazdanbakhsh for discussion and advice and Janice Murray for
assistance with the filarial life cycle. Bm33 cDNA was kindly supplied
by S. Dissanayake.
REFERENCES
1. Ash, L. R., and J. M. Riley. 1970. Development of subperiodic Brugia malayi
in the jird, Meriones unguiculatus, with notes on infections in other rodents.
J. Parasitol. 56:969–973.
2. Bianco, A. E., B. D. Robertson, Y.-M. Kuo, S. Townson, and P. Ham. 1990.
Developmentally regulated expression and secretion of a polymorphic anti-
gen by Onchocerca infective-stage larvae. Mol. Biochem. Parasitol. 39:203–
212.
3. Bianco, A. E., Y. Wu, and R. E. Jenkins. 1995. Onchocerca spp: a “family” of
secreted acidic proteins expressed by infective larvae in blackflies. Exp.
Parasitol. 81:344–354.
4. Day, K. P. 1991. The endemic normal in filariasis: a static concept. Parasitol.
Today 7:341–343.
5. Day, K. P., W. F. Gregory, and R. M. Maizels. 1991. Age-specific acquisition
of immunity to infective larvae in a Bancroftian filariasis endemic area of
Papua New Guinea. Parasite Immunol. 13:277–290.
6. Day, K. P., B. Grenfell, R. Spark, J. W. Kazura, and M. P. Alpers. 1991. Age
specific patterns of change in the dynamics of Wuchereria bancrofti infection
in Papua New Guinea. Am. J. Trop. Med. Hyg. 44:518–527.
7. Dissanayake, S., M. Xu, C. Nkenfou, and W. F. Piessens. 1993. Molecular
cloning and serological characterization of a Brugia malayi pepsin inhibitor
homolog. Mol. Biochem. Parasitol. 62:143–146.
8. Frank, G. R., and R. B. Grieve. 1991. Metabolic labeling of Dirofilaria immitis
third- and fourth-stage larvae and their excretory-secretory products. J. Para-
sitol. 77:950–956.
9. Frank, G. R., and R. B. Grieve. 1995. Purification and characterization of
three larval excretory-secretory proteins of Dirofilaria immitis. Mol. Bio-
chem. Parasitol. 75:221–229.
10. Frank, G. R., C. A. Tripp, and R. B. Grieve. 1995. Molecular cloning of a
developmentally regulated protein isolated from excretory-secretory prod-
ucts of larval Dirofilaria immitis. Mol. Biochem. Parasitol. 75:231–240.
11. Freedman, D. O., T. B. Nutman, and E. A. Ottesen. 1989. Protective immu-
nity in Bancroftian filariasis: selective recognition of a 43-kD larval stage
antigen by infection-free individuals in an endemic area. J. Clin. Invest.
83:14–22.
12. Gems, D. H., C. J. Ferguson, B. D. Robertson, A. P. Page, M. L. Blaxter, and
R. M. Maizels. 1995. An abundant, trans-spliced mRNA from Toxocara canis
infective larvae encodes a 26 kDa protein with homology to phosphatidyleth-
anolamine binding proteins. J. Biol. Chem. 270:18517–18522.
13. Gregory, W. F., M. L. Blaxter, and R. M. Maizels. 1997. Differentially
expressed, abundant trans-spliced cDNAs from larval Brugia malayi. Mol.
Biochem. Parasitol. 87:85–95.
14. Hussain, R., M. Gro¨gl, and E. A. Ottesen. 1987. IgG antibody subclasses in
human filariasis: differential subclass recognition of parasite antigens corre-
lates with different clinical manifestations of infection. J. Immunol. 139:
2794–2798.
15. Joseph, G. T., T. Huima, and S. Lustigman. 1998. Characterization of an
Onchocerca volvulus L3-specific larval antigen, Ov-ALT-1. Mol. Biochem.
Parasitol. 96:177–183.
16. Kazura, J. W., T. B. Nutman, and B. M. Greene. 1993. Filariasis: immunol-
ogy and molecular biology of parasitic infections, 3rd ed., p. 473–495. Black-
well Scientific Publications, Boston, Mass.
17. Kurniawan, A., E. Sartono, F. Partono, M. Yazdanbakhsh, and R. M.
Maizels. 1998. Antibody responses to filarial infective larvae are not domi-
nated by the IgG4 isotype. Parasite Immunol. 20:9–17.
18. Kurniawan, A., M. Yazdanbakhsh, R. van Ree, R. Aalberse, M. E. Selkirk, F.
Partono, and R. M. Maizels. 1993. Differential expression of IgE and IgG4
specific antibody responses in asymptomatic and chronic human filariasis.
J. Immunol. 150:3941–3950.
19. Li, B.-W., R. Chandrashekar, R. M. Alvarez, F. Liftis, and G. J. Weil. 1991.
Identification of paramyosin as a potential protective antigen against Brugia
malayi infection in jirds. Mol. Biochem. Parasitol. 49:315–324.
20. Li, B.-W., R. Chandrashekar, and G. J. Weil. 1993. Vaccination with recom-
binant filarial paramyosin induces partial immunity to Brugia malayi infec-
tion in jirds. J. Immunol. 150:1881–1885.
21. Li, B.-W., S. Zhang, K. C. Curtis, and G. J. Weil. 1999. Immune responses
to Brugia malayi paramyosin in rodents after DNA vaccination. Vaccine
18:76–81.
22. Maizels, R. M., M. Holland, F. H. Falcone, X. X. Zang, and M. Yazdanba-
khsh. 1999. Vaccination against helminth parasites: the ultimate challenge
for immunologists? Immunol. Rev. 171:125–148.
23. Maizels, R. M., and R. A. Lawrence. 1991. Immunological tolerance: the key
feature in human filariasis? Parasitol. Today 7:271–276.
24. Maizels, R. M., B. D. Robertson, M. L. Blaxter, and M. E. Selkirk. 1991.
Parasite antigens, parasite genes: a laboratory manual for molecular parasi-
tology. Cambridge University Press, New York, N.Y.
25. Maizels, R. M., E. Sartono, A. Kurniawan, M. E. Selkirk, F. Partono, and M.
Yazdanbakhsh. 1995. T cell activation and the balance of antibody isotypes
in human filariasis. Parasitol. Today 11:50–56.
26. Michael, E., D. A. P. Bundy, and B. T. Grenfell. 1996. Re-assessing the global
prevalence and distribution of lymphatic filariasis. Parasitology 112:409–428.
27. Nutman, T. B. 1989. Protective immunity in lymphatic filariasis. Exp. Para-
sitol. 68:248–252.
28. Nutman, T. B. (ed.). 1999. Lymphatic filariasis. Imperial College Press,
London, U.K.
29. Ottesen, E. A. 1992. Infection and disease in lymphatic filariasis: an immu-
nological perspective. Parasitology 104:S71–S79.
30. Peralta, M. E., K. A. Schmitz, and T. V. Rajan. 1999. Failure of highly
immunogenic filarial proteins to provide host-protective immunity. Exp.
Parasitol. 91:334–340.
31. Pogonka, T., U. Oberlander, T. Marti, and R. Lucius. 1999. Acanthochei-
lonema viteae: characterization of a molt-associated excretory/secretory 18-
kDa protein. Exp. Parasitol. 93:73–81.
32. Selkirk, M. E., R. M. Maizels, and M. Yazdanbakhsh. 1992. Immunity and
the prospects for vaccination against filariasis. Immunobiology 184:263–281.
33. The Filarial Genome Project. 1999. Deep within the filarial genome: an
update on progress in the Filarial Genome Project. Parasitol. Today 15:219–
224.
34. World Health Organization. 1992. Lymphatic filariasis: the disease and its
control. Fifth Report of the WHO Expert Committee on Filariasis. World
Health Organization, Geneva, Switzerland.
35. Yates, J. A., and G. I. Higashi. 1985. Brugia malayi: vaccination of jirds with
60cobalt-attenuated infective stage larvae protects against homologous chal-
lenge. Am. J. Trop. Med. Hyg. 34:1132–1137.
36. Zang, X. X., M. Yazdanbakhsh, H. Kiang, M. R. Kanost, and R. M. Maizels.
1999. A novel serpin expressed by the blood-borne microfilariae of the
parasitic nematode Brugia malayi inhibits human neutrophil serine protein-
ases. Blood 94:1418–1428.
Editor: W. A. Petri, Jr.
VOL. 68, 2000 CANDIDATE VACCINE ANTIGENS FOR FILARIASIS 4179
